5 High Growth Micro-cap Stocks to Buy

Page 5 of 5

1. Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)

Latest QTR YoY Revenue Growth: 5,120%

Number of Hedge Fund Holders: 18

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) is a California-based company that develops treatments for immune-mediated dermatological diseases and conditions.

On November 29, Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) announced that its roflumilast cream for seborrheic dermatitis received FDA approval. Called Zoryve, the company expects to launch the cream by the end of January 2024.

For the third quarter, Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) posted its earnings result with a GAAP EPS of -$0.73, which beat the estimates by $0.15. The revenue of $38.1 million surpassed the estimates by $7.28 million, an increase of more than 5,000% YoY.

In the third quarter, 18 hedge funds held a stake in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)’s stock, compared to 17 in the previous quarter. With 5.034 million shares worth $26,733 million, David Rosen’s Rubric Capital Management was the biggest stakeholder in the company.

Follow Arcutis Biotherapeutics Inc. (NASDAQ:ARQT)

You can also look at the 11 Best Shipping Stocks That Pay Dividends and the Stagflation Definition: 11 Best Stagflation Stocks To Buy.

Insider Monkey focuses on uncovering the best investment ideas of hedge funds and investors. Please subscribe to our daily free newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.

Page 5 of 5